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Background: The incidence of brain metastasis from hepatocellular carcinoma (HCC) is expected to increase as a
result of prolonged survival due to the recent advances in HCC treatment. However, there is no definite treatment
strategy for brain metastasis from HCC mainly due to its rarity and dismal prognosis. To provide helpful
recommendations in treatment of brain metastasis from HCC, the authors aimed to identify prognostic factors that
influence survival rates with a review of the recently published data.
Methods: Thirty-three cases of brain metastasis, whose incidence was 0.65%, were selected from a total of 5015
HCC patients and reviewed retrospectively in terms of clinical and radiological features.
Results: Median overall survival time after diagnosis of brain metastasis was 10.4 weeks (95% confidence interval
[CI], 5.1-15.7 weeks) with 1-, 6- and 12-month survival rates, of 79%, 24% and 6%, respectively. Median survival of
the patients treated with surgical resection or surgical resection followed by whole-brain radiation therapy (WBRT)
(25.3 weeks; range, 15.8-34.8 weeks) was longer than that of the patients treated with gamma knife surgery (GKS),
WBRT, or GKS followed by WBRT (10.4 weeks; range, 7.5-13.3 weeks) as well as that of patients treated with only steroids
(1 week; range, 0.0-3.3 weeks) (p < 0.001). Child-Pugh’s classification A group had a longer median survival time than
Child-Pugh’s classification B or C group (14.4 weeks vs 8.4 weeks, p = 0.038). RPA class I & II group had also a longer
median survival time than RPA class III group did (13.4 weeks vs 2.4 weeks, p = 0.001). Surgical resection (hazard ratio
[HR] 0.23, 95% CI 0.08-0.66, p = 0.006) and good liver function at the time of brain metastasis (HR 0.25, 95% CI 0.09-0.69,
p = 0.007) were found to be the powerful prognostic factors for favorable survival in the multivariate analysis. In
addition, presence of intratumoral hemorrhage was a statistically significant prognostic factor for survival.
Conclusion: Although HCC patients with brain metastasis showed a very dismal prognosis, surgical intervention was
shown to lead to relative prolongation of the survival time, especially in those with preserved hepatic function.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumors worldwide [1]. Its incidence is par-
ticularly high in Southeast Asia and sub-Saharan Africa
where hepatitis B and C infections are the most prevalent
[1]; however, a significant increase in the incidence of HCC
has been recently observed in Australia and other Western
countries [1]. Brain metastasis from HCC is so rare that
the incidence was reported to be only about 0.6% [2]. The* Correspondence: moonks@chonnam.ac.kr
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reproduction in any medium, provided the orrecent therapeutic advances including surgical techniques,
transarterial chemoembolization (TACE), local ablation,
and chemotherapeutic agents, have all contributed to im-
proved survival rates [3]. The incidence of brain metastasis,
therefore, is expected to increase as a result of prolonged
survival of HCC patients [4]. The prognosis for patients
having brain metastasis from HCC is very poor [5-7].
There have been no definite recommendations for the
management of the brain metastasis from HCC, because
of its rarity and poor prognosis.
In the present study, the authors aimed to elucidate
the incidence of brain metastasis from HCC and to
identify prognostic factors that influence survival rates.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nostic factors for survival in patients with brain metas-
tasis from HCC.
Methods
The study is in compliance with the Declaration of
Helsinki (Sixth Revision, 2008). This study fulfills all the
requirements for patient anonymity was approved by the
institutional review board of Chonnam National University
Medical School Research Institution (2013–67). Of a total
5015 HCC patients who were diagnosed and treated at
our hospital between 2001 and 2012, 33 patients were
retrospectively confirmed as having brain metastasis from
HCC, using cranial computed tomography (CT) and/or
magnetic resonance imaging (MRI) and by reviewing
the hospital charts.
To define the clinical characteristics of the patients
with brain metastasis from HCC, clinical data at the time of
diagnosis of brain metastasis, including age, sex, presenting
symptoms, time interval from diagnosis of primary tumor
to brain metastasis, Eastern cooperative oncology group
(ECOG) performance status [8], Child-Pugh classification
[9], recursive partitioning analysis (RPA) class [10], level of
alpha fetoprotein (AFP), treatment modality, and survival
time were collected. Additionally, we also evaluated the
radiological findings such as the presence of extracranial
metastasis and main portal vein thrombosis, number and
type of HCC nodule, size of the largest HCC nodule, num-
ber of brain lesions, concomitant intratumoral hemorrhagic
changes and location of the brain lesion.
ECOG performance status described six grades to
determine the appropriate treatment and prognosis [8]:
Grade 0: Fully active, able to carry on all pre-disease
performance; Grade 1: Restricted in physically strenuous
activity but ambulatory and able to carry out work of a light
or sedentary nature; Grade 2: Ambulatory and capable of
all self-care but unable to carry out any work activities,
Up and about more than 50% of waking hours; Grade
3: Capable of only limited self-care, confined to bed or chair
more than 50% of waking hours; Grade 4: Completely
disabled. Cannot carry on any self-care. Totally confined
to bed or chair; Grade 5: Dead.
Child-Pugh classification [9] includes the factors of
hepatic encephalopathy, ascites, total bilirubin level, albu-
min level, and prolonged prothrombin time. Child-Pugh
A category is defined as a score of 5–6, Child-Pugh B
category is defined as a score of 7–9, and Child-Pugh
C category is defined as a score of 10–15. Overall survival
was calculated from the date of diagnosis of brain metas-
tasis until death, or until the date of the last follow-up visit
for patients who were still alive.
RPA classification describes three classes to predict
survival of patients with brain metastases [10]: Class I:
patients with a Karnofsky performance status (KPS) > 70,age < 65 years with controlled primary disease and no
evidence of extracranial metastases; Class III: patients
with a KPS < 70, and Class II: all remaining patients who do
not fit into Classes 1 or III. Stratified Mantel-Cox log-rank
test for each factor was applied to compare the Kaplan-
Meier curves for survival. The factors that might predict
overall survival in HCC patients with brain metastasis were
analyzed using a multivariate logistic regression model. All
statistical analyses were performed using SPSS version 20.0
software program for Windows (SPSS, Chicago, IL, USA).
The level of significance was set at P < 0.05.
Results
Clinical presentation
The incidence of brain metastasis from HCC was 0.65%
in our patient group (33/5015). Clinical characteristics of
the enrolled patients are summarized in Table 1. The
median age at diagnosis of brain metastasis was 62 years
(range, 23–80 years) and there was a male predominance
(91%). The most common presenting symptoms were
headache, followed by motor weakness and mental status
changes. The majority of the lesions were symptomatic
(97%), possibly due to the high incidence of intratumoral
hemorrhage (52%). The median time interval between diag-
nosis of HCC and diagnosis of brain metastasis was
18.3 months (range, 0.5-75 months). In RPA classification
at the time of diagnosis of brain metastasis, the majority of
the patients were grouped into class II (27 patients, 82%) or
III (4 patients, 12%). According to Child-Pugh classification
for the severity of liver function, 20 patients (61%) were
classified into grade A, 13 patients (39%) into grade B or C.
Elevated AFP levels were found in only 10 patients (30%).
Viral hepatitis infection was detected in most of the pa-
tients (85%) on serological study with a high prevalence of
hepatitis B virus infection (76%). In the aspect of HCC
characteristics, only 8 patients (24%) showed smaller num-
ber of nodule lesser than 4 (<4). The maximum diameter of
the HCC nodule was greater than 5 cm in 15 patients
(45%). Ill-defined types of HCC were found in 13 patients
(39%) and thrombosis of the main portal vein was present
in 15 patients (45%). Chemotherapy using a target agent
(Sorafenib®) was applied in 10 patients (30%).
Twenty-four patients (73%) had lung metastasis at the
time of detection of brain metastasis. Seventeen patients
(52%) had a single brain lesion.
Treatment
Accordingly, treatment methods were decided based on
many factors, including general condition of the patient,
the number and location of brain lesions, physician’s
and patients’ personal preference. Treatment modalities
for brain metastasis are summarized in Table 1. Ten
patients underwent surgical resection and six of them
subsequently received WBRT. Thirteen patients were
Table 1 Clinical characteristics of 33 patients with brain
metastases from HCC
Characteristic No. of patients (%)
HCC characteristics
Age in years at diagnosis of





Time in months from diagnosis of HCC

















Hepatitis B 25 (76%)
Hepatitis C 3 (9%)
Alcoholic 4 (12%)
Idiopathic 1 (3%)
















Hepatic resection 5 (15%)
Table 1 Clinical characteristics of 33 patients with brain
metastases from HCC (Continued)
TACE 27 (82%)
RFA 4 (12%)
Chemotherapy (Sorafenib) 10 (30%)
Radiotherapy 10 (30%)
Site of extracranial metastases
Lung 24 (73%)
Bone 6 (18%)
Lymph node 8 (24%)






Motor disturbance 12 (36%)
Mental status changes 8 (24%)
Visual disturbance 5 (15%)
Dizziness 4 (12%)













Cavernous sinus 1 (3%)
Basal ganglia 1 (3%)
Multiple locations 16 (48%)
Treatment modalities
Resection alone 4 (12%)
Resection + WBRT 6 (18%)
GKS alone 11 (33%)
GKS + WBRT 2 (6%)
WBRT alone 4 (12%)
Palliative (Steroid alone) 6 (18%)
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WBRT alone. Two patients who were previously treated
with GKS showed tumor recurrence, and hence additional
WBRT was performed in these patients. Six patients
received conservative medical (palliative) treatment, mainly
with steroids to reduce the increased intracranial pres-
sure. All operation cases underwent gross total resec-
tion. Mean maximal and marginal doses of GKS were
36.4 Gy (range, 24–50 Gy) and 18 Gy (range, 14–25 Gy)
prescribed to the 50% iso-dose line. The usual fractionation
schedule for WBRT was 30 Gy in 10 fractions (Mean dose,
28.8 Gy ; range, 25–30 Gy).
Overall survival and prognostic factors
Patients with brain metastasis from HCC had poor out-
comes. The median overall survival time after diagnosis of
brain metastasis was 10.4 weeks (Figure 1. 95% confidence
interval [CI]: 5.1-15.7 weeks). The 1-, 6- and 12-month sur-
vival rates were 79%, 24% and 6%, respectively. At the end
of the follow up, 31 patients had died and two patients were
alive (one in radiation treatment group and one resection
group). The cause of death was identified in 29 patients
(not defined in two cases; one in radiation treatment group
and one in resection group). Seventeen patients died as a
result of progressive diseases or systemic complications
(hepatic failure, acute respiratory failure, and so on), and 12
patients died as a consequence of metastatic brain diseases.
With palliative treatment using steroid, 5 patient died
due to brain lesions (5/6, 83%). In the radiation treatment
group, causes of death were neurologic-origin in 6 patients
(6/15, 40%). Only one patients (1/8, 13%) died fromFigure 1 Overall survival in 33 patients after the diagnosis of
brain metastasis from HCC. Note that the median survival was
10.4 weeks and 1-, 6- and 12-month survival rates were 79%, 24%
and 6%, respectively.neurologic cause (rebleeding on another small lesion)
in the surgical resection group.
The results of analyses of the variables that could be
correlated with survival time are shown in Table 2. On
univariate analysis, RPA classification, Child-Pugh’s classifi-
cation, intratumoral hemorrhage, and treatment modality
showed statistical significance (Figure 2). The patients with
RPA class I or II showed a longer survival time than the pa-
tients with RPA class III did, with a statistical significance
in univariate analysis (13.4 weeks vs 2.4 weeks, p = 0.001).
In multivariate analysis, however, this difference was not
statistically significant (p = 0.063).
Child-Pugh’s classification A group had a longer median
survival time than Child-Pugh’s classification B or C group
(14.4 weeks vs 8.4 weeks, p = 0.038). The statistical sig-
nificance remained meaningful in multivariate analysis
(HR 0.25, 95% CI 0.09-0.69, p = 0.007). Patients with-
out intratumoral hemorrhage had a longer median sur-
vival time than patients with intratumoral hemorrhage
(13.7 weeks vs 8.1 weeks, p = 0.044). Furthermore, this
difference reached statistical significance in multivariate
analysis (HR 0.19, 95% CI 0.07-0.55, p = 0.002). With
respect to the treatment modality for brain metastasis,
surgical treatment was shown to lead to a longer survival
time in univariate analysis (p < 0.001); Median survival was
25.3 weeks (range, 15.8-34.8 weeks) for patients treated
with surgical resection/surgical resection followed by
WBRT, 10.4 weeks (range, 7.5-13.3 weeks) for patients
treated with GKS followed by WBRT/GKS/WBRT, and
only 1 week (range, 0.0-3.3 weeks) for patients treated with
only steroids. In multivariate analysis, surgical resection was
significantly associated with longer survival compared
to non-resection treatment (HR 0.23, 95% CI 0.08-0.66,
p = 0.006). Interestingly, the patients with a shorter interval
(≤12 months) from diagnosis of primary tumor to brain
metastasis showed a longer survival time than the patients
with a longer interval (>12 months) from diagnosis of
primary tumor to brain metastasis, without statistical
significance in multivariate analysis (15.6 weeks vs 8.7 weeks,
p = 0.089). The younger age group (<60 years) survived
longer than the older age group, but the difference was not
statistically significant in multivariate analysis (14.8 weeks
vs 8.7 weeks, p = 0.062).
As shown in Figure 3, the univariate analysis demon-
strated that HCC characteristics including the number
of nodule, size of the largest nodule, type and presence
of portal vein thrombosis were not correlated with the
survival rate of the patients. In multivarate analysis, the
patients without portal vein thrombosis survived longer
than the patients with thrombosis did, with marginal stat-
istical significance (10.4 weeks vs 8.7 weeks, p = 0.065).
The group with well-defined HCC type or HCC nodule
less than 4 showed a longer survival than the group with
ill-defined type or nodule over than 4. However, these
Table 2 Univariate and multivariate analyses for survival




p-value HR 95% CI p-value
AGE
0.096 ND<60 years 17 14.8 0.062
≥60 years 16 8.7
Sex
0.178 NDM 30 10.4 0.144
F 3 8.4
Symptoms#
0.412 NDMinor 17 11.6 0.552
Major 16 8.1
Interval of diagnosis from primary
tumor to brain metastasis
≤12 months 11 15.6 0.239 ND 0.089
>12 months 22 8.7
ECOG PS
0.655 ND≤2 21 13.4 0.707
>2 12 4.7
RPA class
0.001 NDI & II 29 13.4 0.575
III 4 2.4
Child-Pugh’s classification
A 20 14.4 0.038 0.25 0.09-0.69 0.007
B/C 13 8.4 1
Number of HCC nodules
1-3 18 9.6 0.389 ND 0.088
≥4 10 8.7
Largest size of HCC
≤5 cm 18 14.4 0.094 ND 0.119
>5 cm 15 6.0
HCC type
Well-defined 20 12.9 0.210 ND 0.072
Ill-defined 13 8.7
Main portal vein thrombosis
No 18 10.4 0.202 ND 0.065
Yes 15 8.7
Chemotherapy for HCC (Sorafenib)
No 23 9.6 0.735 ND 0.583
Yes 10 10.4
AFP
≤400 18 9.6 0.389 ND 0.174
>400 10 8.7
Lung metastasis
No 9 21.9 0.197 ND 0.956
Yes 24 9.4
Table 2 Univariate and multivariate analyses for survival
predictors in patients with brain metastasis from HCC
(Continued)
Number of brain metastasis
Single 17 13.7 0.341 ND 0.800
Multiple 16 8.1
Hemorrhage of brain metastasis
No 16 13.7 0.044 0.19 0.07-0.55 0.002
Yes 17 8.1 1
Treatment for brain metastasis




Steroid alone 6 1.0
# Minor; headache, dizziness, cranial nerve deficit, Major; mental status
changes, motor weakness.
* Reference variable: non-resection treatment groups.
HCC; hepatocellular carcinoma, wks; weeks, AFP; alpha fetoprotein, WBRT;
whole brain radiation therapy, GKS; gamma knife radiosurgery, ND; not
determined.
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variate analysis (HCC type [10.4 weeks vs 8.7 weeks, p =
0.072], number of nodule [9.6 weeks vs 8.7 weeks, p =
0.088]). Additionally, the usage of chemotherapeutic target
agent (Sorafenib®) for HCC did not affect the patients’ sur-
vival (10.4 weeks vs 9.6 weeks, p = 0.583).
Discussion
The incidence of brain metastasis in patients with
HCC at our hospital was 0.65%, and this finding was in
accordance with in previous reports demonstrating
an incidence ranging from 0.26 to 2.2% [5,11]. However,
these numerical values probably underestimate the true
incidence. In our hospital, brain imaging study is not a
routine evaluation for HCC patients; and it is performed
mainly in cases with neurologic symptoms. Therefore,
asymptomatic patients with brain metastasis may have
been missed. In this study, only one patient (3%) was
asymptomatic and found on a routine work-up for sys-
temic progression.
The prognosis of brain metastasis from HCC is extremely
poor. As summarized in Table 3, in the previously reported
large studies, the median survival for patients with brain
metastasis from HCC was from 4 to 12 weeks [5-7,12,13].
Similarly, the median survival was 10.4 weeks in our study.
In a study by Han et al. [7], patients treated with WBRT
and/or GKS had a longer median survival time than
patients treated with surgical resection followed by WBRT
(16 weeks vs 8 weeks). However, other studies have re-
ported that surgical treatment may confer a survival
benefit in patients with brain metastasis from HCC
[5,6,13]. In our study, patients treated with surgical resec-
tion with/without postoperative WBRT had a longer me-
dian survival time than patients treated with GKS followed
Figure 2 Kaplan-Meier analyses of overall survival for 33 patients according to different predictors. (overall comparison was estimated using a
log-rank test). A: RPA class, B: Child-Pugh classification, C: Presence of intratumoral hemorrhage, D: Treatment modality for brain metastasis.
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roids (25.3 weeks vs 10.4 weeks vs 1.0 week, p < 0.001). Fur-
thermore, surgical resection was one of the most powerful
prognostic factor for favorable survival in the multivariate
analysis. (HR 0.23, 95% CI 0.08-0.66, p = 0.006).
The treatment for intracranial metastasis from HCC may
be similar to the general guidelines on metastatic brain
tumors. In a single large lesion (>3 cm), especially with a
significant mass effect (>1 cm midline shift), surgical resec-
tion should be considered with/without following whole
brain radiotherapy (WBRT). Although the role of surgical
resection for multiple brain metastases has not been estab-
lished, surgery could be tried in cases with large lesions or
significant mass effects and in cases where two or more le-
sions are accessible through a single craniotomy approach
[14]. In the present study, it is difficult to conclude how
the surgical resection could extend the patient’s survival.
Surgical resection decreased the possibility of the death
from neurologic origins (13% in surgical resection group vs
40% in radiation treatment group and 83% in palliative
treatment group). This finding might be explained by theclinical course of hemorrhagic HCC metastasis. Han et al.
[7] found that recurrent intracranial bleeding after treat-
ment was frequently found in the patients who had pre-
sented with overt intratumoral hemorrhage. However, the
patients who did better after surgical resection were likely
the group of patients who had intracranial lesions in a less
eloquent area or better overall prognostic factors or health
status. This would confound the results in a view of treat-
ment effect versus patient selection effect.
Child-Pugh classification was also an important prog-
nostic factor in our analysis. Child-Pugh classification is
the most commonly used criterion to evaluate the status
of liver function. The rate of complications, hemorrhage
and mortality increase with poor liver function, especially
in patients with HCC or liver cirrhosis [15]. Choi et al.
[6] reported that the Child-Pugh classification was shown
to influence the median survival time in patients with
brain metastasis from HCC. In our study, Child-Pugh
classification A group had a longer median survival time
than Child-Pugh classification B/C group (14.4 weeks vs
4.7 weeks, p = 0.038). On multivariate analysis, good liver
Figure 3 Kaplan-Meier analyses of overall survival for 33 patients according to HCC characteristics. (overall comparison was estimated
using a log-rank test). A: Number of nodule, B: Size of the largest nodule, C: Type of HCC, D: Presence of portal vein thrombosis.
Han et al. BMC Cancer 2013, 13:567 Page 7 of 9
http://www.biomedcentral.com/1471-2407/13/567function at the time of brain metastasis was one of the
most powerful prognostic factor for favorable survival
(HR 0.06, 95% CI 0.01-0.37, p = 0.002).
The median interval from initial HCC diagnosis to brain
metastasis was 18.3 months in our study. It was similar to
that in the previous studies, with the median interval ran-
ging from 10.5 to 18.5 months. Some investigators, despite
statistical insignificance, reported that the patients with a
longer interval (≥12 months) from initial HCC diagnosis
to brain metastasis had a relatively longer survival than
patients with a shorter interval (<12 months) from initial
HCC diagnosis to brain metastasis [6,13]. In our study,
however, the patients with a shorter interval (<12 months)
from diagnosis of primary tumor to brain metastasis showed
longer survival than the patients with a longer interval
(≥12 months) from diagnosis of primary tumor to brain
metastasis without statistical significance in multivariate
analysis (15.6 weeks vs 8.7 weeks, p = 0.089). Presum-
ably, this result may be due to the declining general
conditions of HCC patients. In other words, patients
with a longer interval from diagnosis of primary tumorto brain metastasis might have worse general conditions
following prolonged clinical progression than patients
with a shorter interval from diagnosis of primary tumor
to brain metastasis.
Previous studies have reported that brain metastasis
from HCC is frequently associated with intratumoral
hemorrhage [5-7,12,13]. This can be explained by the
hypervascularity of HCC or a possible coagulopathy due
to liver cirrhosis [6]. There is a controversy over the effect
of intratumoral hemorrhage of brain metastasis on survival
in HCC patients. Jiang et al. [13] reported that the patients
without intratumoral hemorrhage had a longer survival
time than patients with intratumoral hemorrhage, although
statistical significance was not reached. Hsieh et al. [12], on
the contrary, reported that the presence of intratumoral
hemorrhage did not influence the overall survival in pa-
tients with brain metastasis from HCC. In our study, 51.5%
of patients presented with intratumoral hemorrhage, and
patients without intratumoral hemorrhage had a longer
survival time than patients with intratumoral hemorrhage
(13.7 weeks vs 8.1 weeks, p = 0.044 in univariate analysis).





















Choi et al. (2009) 62 54 18.2 6.8 Resection and WBRT 33.6 Single lesion, Child-Pugh’s
classification A Any treatment




Hsieh et al. (2009) 42 55.8 15.4 4.8 NA NA ICH did not influence
Han et al. (2010) 20 55 18.5 8 Resection and WBRT 8 Younger age, Extracranial
metastasis
WBRT and/or GKS 16
Jiang et al. (2012) 41 48.5 15 12 Resection or WBRT
or GKS
18 No extracranial metastasis,
Low RPA class, Any treatment
modalities for brain metastasis
Steroids alone 10.8
Present Study (2013) 33 62 18.3 10.4 Resection/
Resection+WBRT
25.3 No intratumoral bleeding
Child-Pugh’s classification A,
Resection for brain metastasis
WBRT/GKS/WBRT+GKS 10.4
Steroids alone 1.0
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was the one of the prognostic factors for patient survival
(HR 0.19, 95% CI 0.07-0.55, p = 0.002). As previously
noted, hemorrhagic events frequently recurred in the
cases with intratumoral hemorrhage, always drawn into
the dismal prognosis. In addition, sudden neurological
deterioration as in cerebrovascular accidents can lead to
severe neurological deficits and poor functional status,
which made the patients hesitating in selection for
further adjuvant treatments, especially in the patients
with underlying coagulopathy due to poor liver function
state.
The RPA class has been suggested as an independent
prognostic factor for the patients with brain metastasis
from HCC. This result implies that patients with RPA
class I and II may benefit from aggressive treatment
[13]. Some studies revealed that the patient with low
RPA class demonstrated longer survival than those with
high RPA class [6,7]. Although patients with low RPA
class (I and II) survived longer than patients with RPA
class III in univariate analysis (13.4 weeks vs 2.4 weeks,
p = 0.001) in our study, RPA class was not an independ-
ent prognostic factor in multivariate analysis (p = 0.575).
The number of metastatic brain lesions can be an im-
portant prognostic factor. It was reported that the pa-
tients with single lesions had a longer survival time than
the patients with multiple lesions [6]. Similarly, in our
study, the median survival of patients with a single le-
sion was longer than that of patients with multiple le-
sions, although statistical significance was not reached
(13.7 weeks vs. 8.1 weeks, p = 0.341). Han et al. [7]reported that younger patients less than 60 years of age
can be considered as a positive prognostic factor. Our
study also showed that younger patients survived longer
than older patients with a marginal statistical signifi-
cance (14.8 weeks vs 8.7 weeks, p = 0.096). However,
younger age was not an independent favorable prognos-
tic factor in the multivariate analysis (p = 0.062). Al-
though good performance status (ECOG performance
status grade 0–2) has been reported as a positive prog-
nostic factor [6], it did not show statistical significance
as a prognostic factor in our study. HCC characteristics
including the number of nodule, size of the largest nod-
ule, type and presence of portal vein thrombosis were
not correlated with the survival time of the patients. Fur-
thermore, these were not independent prognostic factors
in multivariate analysis, despite marginal statistical sig-
nificances in some factors (presence of portal vein
thrombosis [p = 0.065], HCC type [p = 0.065], number of
nodule [p = 0.088]).
Conclusion
Although there have been some studies for identifying the
prognostic factors for HCC patients with brain metastasis,
it is challenging to specify the appropriate therapeutic
strategy considering its rare incidence and poor prognosis.
This study was basically a retrospective investigation
of a relatively small number of patients. Therefore,
there may be a possibility of selection bias and missed
cases. And there was no information of the quality of
life in the patients after various treatment modalities. To
determine an appropriate therapeutic strategy for patients
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randomized study based on the survival and quality of
life is needed.
In addition to the treatment modality for brain metasta-
sis and liver function at the diagnosis of brain metastasis,
presence of intratumoral hemorrhage was an independent
prognostic factors for survival. Although HCC patients
with brain metastasis showed a very poor prognosis with
a 1-year survival rate of 6%, surgical intervention was
shown to lead to relative prolongation of the survival time,
especially in those with preserved hepatic function.
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